<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方Info | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-21T20:43:46+08:00</updated>
  <subtitle>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>挑战K药失败！默克终止M7824一线治疗NSCLC III期研究</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/WUNG2kO_SqeO8xmb7iYByg</id>
    <link href="https://mp.weixin.qq.com/s/WUNG2kO_SqeO8xmb7iYByg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田高血压新药「美阿沙坦钾片」在中国获批上市</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/nyVaivBbu0rpjDqwTDxdkA</id>
    <link href="https://mp.weixin.qq.com/s/nyVaivBbu0rpjDqwTDxdkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/ufmTqGm2DdoMeFKPk2420Q</id>
    <link href="https://mp.weixin.qq.com/s/ufmTqGm2DdoMeFKPk2420Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田「布格替尼片」中国上市申请获受理，治疗NSCLC</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/FSgm1NXVUNSBSBahe0ETaQ</id>
    <link href="https://mp.weixin.qq.com/s/FSgm1NXVUNSBSBahe0ETaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物信迪利单抗+贝伐珠单抗一线治疗肝细胞癌上市申请拟纳入优先审评</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/SChJrZIFOr5SBKthptdAvA</id>
    <link href="https://mp.weixin.qq.com/s/SChJrZIFOr5SBKthptdAvA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌</title>
    <updated>2021-01-21T17:08:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/yXePjtm3amaXN9WDc69zeQ</id>
    <link href="https://mp.weixin.qq.com/s/yXePjtm3amaXN9WDc69zeQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拜耳/默沙东抗心衰新药vericiguat获FDA批准上市</title>
    <updated>2021-01-20T18:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/mc24uto79PhcE5pKGi5rpA</id>
    <link href="https://mp.weixin.qq.com/s/mc24uto79PhcE5pKGi5rpA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>troriluzole治疗轻中度阿尔茨海默症II/III期临床研究失败</title>
    <updated>2021-01-20T18:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/qeAjaf33EwJivx7VhEH6IA</id>
    <link href="https://mp.weixin.qq.com/s/qeAjaf33EwJivx7VhEH6IA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田罕见病新药soticlestat获CDE拟突破性疗法认定</title>
    <updated>2021-01-20T18:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/8nmgpum-eTqG7ETYVnw85A</id>
    <link href="https://mp.weixin.qq.com/s/8nmgpum-eTqG7ETYVnw85A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和铂医药巴托利单抗获CDE拟突破性疗法认定</title>
    <updated>2021-01-20T18:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/Ehsn9mg3KOOojCLeuUdWIg</id>
    <link href="https://mp.weixin.qq.com/s/Ehsn9mg3KOOojCLeuUdWIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康呼吸道合胞病毒预防药物nirsevimab获CDE拟突破性疗法认定</title>
    <updated>2021-01-20T18:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/JjMK80hNRiZ7eWGdefPIFw</id>
    <link href="https://mp.weixin.qq.com/s/JjMK80hNRiZ7eWGdefPIFw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>小分子RNA靶向疗法热潮渐起，全球制药巨头纷涌而至</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/yBePyjnOCIetg692SqvDrg</id>
    <link href="https://mp.weixin.qq.com/s/yBePyjnOCIetg692SqvDrg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>博安生物新冠中和抗体完成 I 期临床全部受试者入组</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/a21EtUlaAfB8FByMElIOwg</id>
    <link href="https://mp.weixin.qq.com/s/a21EtUlaAfB8FByMElIOwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个！博雅辑因CRISPR/Cas 9基因编辑疗法获批临床，治疗β地中海贫血</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/8jSJ1LFkeKInhsCqeLLs0w</id>
    <link href="https://mp.weixin.qq.com/s/8jSJ1LFkeKInhsCqeLLs0w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞克唑替尼新适应症获FDA批准，治疗ALK阳性间变性大细胞淋巴瘤</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/wVndKSCvikc2KMCD82caHg</id>
    <link href="https://mp.weixin.qq.com/s/wVndKSCvikc2KMCD82caHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺华下一代IgE抗体 ligelizumab 获FDA突破性疗法认定</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/jNDWOV2F9sARjhEpH7ehmA</id>
    <link href="https://mp.weixin.qq.com/s/jNDWOV2F9sARjhEpH7ehmA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>临床急需新药「布罗舒单抗」今日在华获批上市</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/DPm8R_mbB-dwI9IBecq7og</id>
    <link href="https://mp.weixin.qq.com/s/DPm8R_mbB-dwI9IBecq7og" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA授予默沙东15价肺炎球菌结合疫苗优先审评资格</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/kSr7nj6P8jRnrLxZUlPZNQ</id>
    <link href="https://mp.weixin.qq.com/s/kSr7nj6P8jRnrLxZUlPZNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国首个! 瑞欣妥®在华重磅获批 绿叶制药创新微球技术展现全球领先优势</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/OguBUdW4kvsi42V9nKT30Q</id>
    <link href="https://mp.weixin.qq.com/s/OguBUdW4kvsi42V9nKT30Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州PD-1第3个适应症获批！一线治疗鳞状NSCLC</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/xzFPNh5u1WxTcTI66LGvbQ</id>
    <link href="https://mp.weixin.qq.com/s/xzFPNh5u1WxTcTI66LGvbQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>